stockrowAclaris Therapeutics, Inc.
ACRS Healthcare Biotechnology
Aclaris Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.8 million, down 58.2% from fiscal 2024.
- Revenue
- −55.1%
- EPS
- 0.00%
- Free cash flow
- −119.9%
Quarter to September 2026, against a year earlier
Follow ACRS
Alert me
Aclaris Therapeutics, Inc. (ACRS) EV/Sales
As of 6 November 2026, Aclaris Therapeutics, Inc. (ACRS) trades at a EV/Sales of 74.4×. Over the past ten years it has ranged from −10.5× (August 2019) to 200× (April 2021); the current reading is higher than 83% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 36.9× | 677.92% |
| FY2024 | 4.7× | — |
| FY2023 | −1.1× | — |
| FY2022 | 26.1× | (72.63%) |
| FY2021 | 95.3× | 166.49% |
| FY2020 | 35.8× | 2,118.76% |
| FY2019 | 1.6× | (91.66%) |
| FY2018 | 19.3× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 107× | 29.98% |
| Jun 2026 | 82.0× | 76.75% |
| Mar 2026 | 46.4× | 25.73% |
| Dec 2025 | 36.9× | 293.17% |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| APMD Apnimed, Inc. compare | −0.2× |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | n/m |
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| BCAX Bicara Therapeutics Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| OBX Obsidian Therapeutics, Inc compare | n/m |
| VALN Valneva SE Sponsored ADR compare | 3.5× |
| ACRS Aclaris Therapeutics, Inc. | 74.4× |
| IAM Iambic Therapeutics, Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)